NICE calls for data to support Alzheimer's drugs

摘要

The National Institute for Health and Clinical Excellence has called for more data from the manufacturers of donepezil,rivastig-mine,galantamine and memantine before it publishes its final guidance on the use of these medicines to treat Alzheimer's disease.Recommendations made by NICE in the first draft of its guidance evoked strong responses from pharmaceutical companies and patient groups who criticised the suggestion that the drugs should not be made available for use within the NHS in England and Wales.